Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
Japan’s Intellectual Property High Court on December 13 turned down Chugai Pharmaceutical’s appeal over a lower-court ruling that rejected its claim for the method-of-use patent of its osteoporosis treatment Edirol (eldecalcitol). “We will consider future measures based on the contents…
To read the full story
Related Article
- Chugai Challenges Ruling in Method-of-Use Patent Case for Edirol
June 10, 2022
- Tokyo Court Nixes Chugai’s Method-of-Use Patent Claim for Edirol
May 30, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
BUSINESS
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
- Ono Teams with Aitia in AI-Driven Neurology Drug Discovery
September 3, 2026
- Nippon Kayaku’s Generic Sunitinib Gains Pancreatic NET Use
September 3, 2026
- GSK Hit with MHLW Guidance over Sponsored Lecture
September 2, 2026
- Nonprescription Cialis Goes Nationwide in Japan, Now at 10,000 Outlets
September 2, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…